Meta-analysis of nonsteroidal anti-inflammatory drug intake and prostate cancer risk

World Journal of Surgical Oncology

Volumn 12, Issue 1, 2014, Pages

  Wang, Xiao ^a   Lin, Yi Wei ^a   Wu, Jian ^a   Zhu, Yi ^a   Xu, Xiang Lai ^a   Xu, Xin ^a   Liang, Zhen ^a   Hu, Zheng Hui ^a   Li, Shi Qi ^a   Zheng, Xiang Yi ^a   Xie, Li Ping ^a  

^a ZHEJIANG UNIVERSITY   (China)

Author keywords

Etiology; Meta analysis; NSAIDs; Prostate cancer

Indexed keywords

ACETYLSALICYLIC ACID; NONSTEROID ANTIINFLAMMATORY AGENT;

ARTICLE; CANADA; CANCER RISK; CASE CONTROL STUDY; CLINICAL EVALUATION; COHORT ANALYSIS; DENMARK; FINLAND; FRANCE; HUMAN; ITALY; META ANALYSIS; NEW ZEALAND; PROSTATE CANCER; UNITED KINGDOM; UNITED STATES; INCIDENCE; MALE; PROGNOSIS; PROSTATIC NEOPLASMS; RISK FACTOR;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; HUMANS; INCIDENCE; MALE; PROGNOSIS; PROSTATIC NEOPLASMS; RISK FACTORS; UNITED STATES;

EID: 84907630335     PISSN: None     EISSN: 14777819     Source Type: Journal    
DOI: 10.1186/1477-7819-12-304     Document Type: Article

References (47)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013, 63(1):11-30. 10.3322/caac.21166, 23335087.
2. Belpomme D, Irigaray P, Ossondo M, Vacque D, Martin M. Prostate cancer as an environmental disease: an ecological study in the French Caribbean islands, Martinique and Guadeloupe. Int J Oncol 2009, 34(4):1037-1044.
3. Wang X, Wang S, Lin YW, Wu J, Chen H, Mao YQ, Zheng XY, Zhou C, Xie LP. Angiotensin-converting enzyme insertion/deletion polymorphism and the risk of prostate cancer in the Han population of China. Med Oncol 2012, 29(3):1964-1971. 10.1007/s12032-011-0051-5, 21874567.
4. Quinn M, Babb P. Patterns and trends in prostate cancer incidence, survival, prevalence and mortality. Part I: international comparisons. BJU Int 2002, 90(2):162-173. 10.1046/j.1464-410X.2002.2822.x, 12081758.
5. Rostom A, Dube C, Lewin G, Tsertsvadze A, Barrowman N, Code C, Sampson M, Moher D. NSAIDs and cyclooxygenase-2 inhibitors for primary prevention of colorectal cancer: a systematic review prepared for the U.S. Preventive Services Task Force. Ann Intern Med 2007, 146(5):376-389. 10.7326/0003-4819-146-5-200703060-00010, 17339623.
6. Corley DA, Kerlikowske K, Verma R, Buffler P. Protective association of aspirin/NSAIDs and esophageal cancer: a systematic review and meta-analysis. Gastroenterology 2003, 124(1):47-56. 10.1053/gast.2003.50008, 12512029.
7. Khuder SA, Mutgi AB. Breast cancer and NSAID use: a meta-analysis. Br J Cancer 2001, 84(9):1188-1192. 10.1054/bjoc.2000.1709, 2363879, 11336469.
8. Vane JR, Bakhle YS, Botting RM. Cyclooxygenases 1 and 2. Annu Rev Pharmacol Toxicol 1998, 38:97-120. 10.1146/annurev.pharmtox.38.1.97, 9597150.
9. Sabichi AL, Lippman SM. COX-2 inhibitors and other NSAIDs in genitourinary cancer. Semin Oncol 2004, 31(2 Suppl 7):36-44.
10. Mahmud SM, Franco EL, Aprikian AG. Use of NSAIDs and prostate cancer risk: a meta-analysis. Int J Cancer 2010, 127(7):1680-1691. 10.1002/ijc.25186, 20091856.
11. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 1959, 22(4):719-748.
12. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986, 7(3):177-188. 10.1016/0197-2456(86)90046-2, 3802833.
13. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003, 327(7414):557-560. 10.1136/bmj.327.7414.557, 192859, 12958120.
14. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997, 315(7109):629-634. 10.1136/bmj.315.7109.629, 2127453, 9310563.
15. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994, 50(4):1088-1101. 10.2307/2533446, 7786990.
16. Paganini-Hill A, Chao A, Ross RK, Henderson BE. Aspirin use and chronic diseases: a cohort study of the elderly. BMJ 1989, 299(6710):1247-1250. 10.1136/bmj.299.6710.1247, 1838122, 2513898.
17. Ratnasinghe LD, Graubard BI, Kahle L, Tangrea JA, Taylor PR, Hawk E. Aspirin use and mortality from cancer in a prospective cohort study. Anticancer Res 2004, 24(5B):3177-3184.
18. Leitzmann MF, Stampfer MJ, Ma J, Chan JM, Colditz GA, Willett WC, Giovannucci E. Aspirin use in relation to risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 2002, 11(10 Pt 1):1108-1111.
19. Sorensen HT, Friis S, Norgard B, Mellemkjaer L, Blot WJ, McLaughlin JK, Ekbom A, Baron JA. Risk of cancer in a large cohort of nonaspirin NSAID users: a population-based study. Br J Cancer 2003, 88(11):1687-1692. 10.1038/sj.bjc.6600945, 2377131, 12771981.
20. Roberts RO, Jacobson DJ, Girman CJ, Rhodes T, Lieber MM, Jacobsen SJ. A population-based study of daily nonsteroidal anti-inflammatory drug use and prostate cancer. Mayo Clin Proc 2002, 77(3):219-225. 10.4065/77.3.219, 11888024.
21. Bosetti C, Talamini R, Negri E, Franceschi S, Montella M, La Vecchia C. Aspirin and the risk of prostate cancer. Eur J Cancer Prev 2006, 15(1):43-45. 10.1097/01.cej.0000180665.04335.de, 16374228.
22. Schreinemachers DM, Everson RB. Aspirin use and lung, colon, and breast cancer incidence in a prospective study. Epidemiology 1994, 5(2):138-146. 10.1097/00001648-199403000-00003, 8172988.
23. Dasgupta K, Di Cesar D, Ghosn J, Rajan R, Mahmud S, Rahme E. Association between NSAIDs and prostate cancer occurrence. Cancer J 2006, 12(2):130-135.
24. Habel LA, Zhao W, Stanford JL. Daily aspirin use and prostate cancer risk in a large, multiracial cohort in the US. Cancer Causes Control 2002, 13(5):427-434. 10.1023/A:1015788502099, 12146847.
25. Nelson JE, Harris RE. Inverse association of prostate cancer and non-steroidal anti-inflammatory drugs (NSAIDs): results of a case-control study. Oncol Rep 2000, 7(1):169-170.
26. Mahmud SM, Tanguay S, Begin LR, Franco EL, Aprikian AG. Non-steroidal anti-inflammatory drug use and prostate cancer in a high-risk population. Eur J Cancer Prev 2006, 15(2):158-164. 10.1097/01.cej.0000197451.02604.25, 16523013.
27. Veitonmaki T, Tammela TL, Auvinen A, Murtola TJ. Use of aspirin, but not other non-steroidal anti-inflammatory drugs is associated with decreased prostate cancer risk at the population level. Eur J Cancer 2013, 49(4):938-945. 10.1016/j.ejca.2012.09.030, 23079475.
28. Jacobs EJ, Rodriguez C, Mondul AM, Connell CJ, Henley SJ, Calle EE, Thun MJ. A large cohort study of aspirin and other NSAIDs and prostate cancer incidence. J Natl Cancer Inst 2005, 97(13):975-980. 10.1093/jnci/dji173, 15998950.
29. Friis S, Sorensen HT, McLaughlin JK, Johnsen SP, Blot WJ, Olsen JH. A population-based cohort study of the risk of colorectal and other cancers among users of low-dose aspirin. Br J Cancer 2003, 88(5):684-688. 10.1038/sj.bjc.6600760, 2376336, 12618874.
30. Shebl FM, Sakoda LC, Black A, Koshiol J, Andriole GL, Grubb R, Church TR, Chia D, Zhou C, Chu LW, Huang WY, Peters U, Kirsh VA, Chatterjee N, Leitzmann MF, Hayes RB, Hsing AW. Aspirin but not ibuprofen use is associated with reduced risk of prostate cancer: a PLCO study. Br J Cancer 2012, 107(1):207-214. 10.1038/bjc.2012.227, 3389420, 22722313.
31. Neugut AI, Rosenberg DJ, Ahsan H, Jacobson JS, Wahid N, Hagan M, Rahman MI, Khan ZR, Chen L, Pablos-Mendez A, Shea S. Association between coronary heart disease and cancers of the breast, prostate, and colon. Cancer Epidemiol Biomarkers Prev 1998, 7(10):869-873.
32. Murad AS, Smith GD, Lewis SJ, Cox A, Donovan JL, Neal DE, Hamdy FC, Martin RM. A polymorphism in the glucokinase gene that raises plasma fasting glucose, rs1799884, is associated with diabetes mellitus and prostate cancer: findings from a population-based, case-control study (the ProtecT study). Int J Mol Epidemiol Genet 2010, 1(3):175-183. 3076770, 21537389.
33. Perron L, Bairati I, Moore L, Meyer F. Dosage, duration and timing of nonsteroidal antiinflammatory drug use and risk of prostate cancer. Int J Cancer 2003, 106(3):409-415. 10.1002/ijc.11250, 12845682.
34. Langman MJ, Cheng KK, Gilman EA, Lancashire RJ. Effect of anti-inflammatory drugs on overall risk of common cancer: case-control study in general practice research database. BMJ 2000, 320(7250):1642-1646. 10.1136/bmj.320.7250.1642, 27410, 10856067.
35. Irani J, Ravery V, Pariente JL, Chartier-Kastler E, Lechevallier E, Soulie M, Chautard D, Coloby P, Fontaine E, Bladou F, Desgrandchamps F, Haillot O. Effect of nonsteroidal anti-inflammatory agents and finasteride on prostate cancer risk. J Urol 2002, 168(5):1985-1988. 10.1016/S0022-5347(05)64277-2, 12394690.
36. García Rodríguez LA, González-Pérez A. Inverse association between nonsteroidal anti-inflammatory drugs and prostate cancer. Cancer Epidemiol Biomarkers Prev 2004, 13(4):649-653.
37. Dhillon PK, Kenfield SA, Stampfer MJ, Giovannucci EL. Long-term aspirin use and the risk of total, high-grade, regionally advanced and lethal prostate cancer in a prospective cohort of health professionals, 1988-2006. Int J Cancer 2011, 128(10):2444-2452. 10.1002/ijc.25811, 3445018, 21128233.
38. Norrish AE, Jackson RT, McRae CU. Non-steroidal anti-inflammatory drugs and prostate cancer progression. Int J Cancer 1998, 77(4):511-515. 10.1002/(SICI)1097-0215(19980812)77:4<511::AID-IJC6>3.0.CO;2-X, 9679750.
39. Brasky TM, Velicer CM, Kristal AR, Peters U, Potter JD, White E. NSAIDs and prostate cancer risk in the VITamins And Lifestyle (VITAL) cohort. Cancer Epidemiol Biomarkers Prev 2010, 19(12):3185-3188. 10.1158/1055-9965.EPI-10-0942, 3005534, 20935064.
40. Platz EA, Rohrmann S, Pearson JD, Corrada MM, Watson DJ, De Marzo AM, Landis PK, Metter EJ, Carter HB. NSAIDs and risk of prostate cancer in the Baltimore Longitudinal Study of Aging. Cancer Epidemiol Biomarkers Prev 2005, 14(2):390-396. 10.1158/1055-9965.EPI-04-0532, 15734963.
41. Menezes RJ, Swede H, Niles R, Moysich KB. Regular use of aspirin and prostate cancer risk (United States). Cancer Causes Control 2006, 17(3):251-256. 10.1007/s10552-005-0450-z, 16489532.
42. Coogan PF, Kelly JP, Strom BL, Rosenberg L. Statin and NSAID use and prostate cancer risk. Pharmacoepidemiol Drug Saf 2010, 19(7):752-755. 10.1002/pds.1970, 2906219, 20582910.
43. Salinas CA, Kwon EM, FitzGerald LM, Feng Z, Nelson PS, Ostrander EA, Peters U, Stanford JL. Use of aspirin and other nonsteroidal antiinflammatory medications in relation to prostate cancer risk. Am J Epidemiol 2010, 172(5):578-590. 10.1093/aje/kwq175, 2950822, 20688905.
44. Mahmud SM, Franco EL, Turner D, Platt RW, Beck P, Skarsgard D, Tonita J, Sharpe C, Aprikian AG. Use of non-steroidal anti-inflammatory drugs and prostate cancer risk: a population-based nested case-control study. PLoS One 2011, 6(1):e16412. 10.1371/journal.pone.0016412, 3030588, 21297996.
45. Lieberman R. Chemoprevention of prostate cancer: current status and future directions. Cancer Metastasis Rev 2002, 21(3-4):297-309.
46. Egger M, Smith GD, Phillips AN. Meta-analysis: principles and procedures. BMJ 1997, 315(7121):1533-1537. 10.1136/bmj.315.7121.1533, 2127925, 9432252.
47. Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, Moher D, Becker BJ, Sipe TA, Thacker SB. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 2000, 283(15):2008-2012. 10.1001/jama.283.15.2008, 10789670.